A tumor marker can change when cancer spreads
Original title: Discordance of PD-L1 expression between primary and paired metastatic non-small cell lung cancer: a systematic review and meta-analysis.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
This pools past studies of real patients, but it does not yet change testing or treatment.
The short version
A lung tumor and the spots where it spread often give different results on the same lab test.
What was studied. Researchers pooled fifteen studies of people with non-small cell lung cancer. The studies compared 1,029 matched pairs of tissue from 1,014 patients. Each pair was one main tumor and one spot where the cancer had spread.
What they found. The test result did not match in 21% of the pairs. Going from positive in the main tumor to negative in the spread spot happened in 26%. Going the other way, negative to positive, happened in 18%. So the marker was more likely to drop in the spread spots. This held up for lymph node and brain spread, but those smaller numbers are early looks only.
What this means, and what it doesn't
What it could mean: This test, called PD-L1, helps doctors decide if immune drugs may work. The tissue used is often an old sample from the first tumor. This work says that old result may not match the cancer that spread. Your doctor may want to weigh it with care.
What it doesn't mean: This is not a new treatment, and it is not a cure for anything. It is a review that pools older studies, not a fresh trial. The authors say it is still unknown whether testing new tissue helps people choose better drugs or live longer. That has to be tested in new studies first. Nothing here changes what care you can get today.
Source: PubMed, October 20, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.